JNJ
Johnson & Johnson
NYSE · Healthcare · Drug Manufacturers - General · US
$275.42
−1.08%0
Insider buys (3m)
9
Insider sells (3m)
-$61.0M
Net value (3m)
+18.6%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Taubert Jennifer L · officer: EVP, WWC. Innovative Medicine | M-Exempt | 15,000 | $116 |
| Aug 18, 2026 | Taubert Jennifer L · officer: EVP, WWC. Innovative Medicine | Sale | 15,000 | $263 |
| Aug 14, 2026 | Duato Joaquin · director, officer: CEO and Chairman of the Board | Sale | 20,976 | $262 |
| Aug 14, 2026 | Duato Joaquin · director, officer: CEO and Chairman of the Board | M-Exempt | 123,291 | $116 |
| Aug 14, 2026 | Duato Joaquin · director, officer: CEO and Chairman of the Board | Sale | 102,315 | $261 |
| Aug 7, 2026 | Forminard Elizabeth · officer: EVP, Chief Legal Officer | M-Exempt | 9,344 | $132 |
| Aug 7, 2026 | Forminard Elizabeth · officer: EVP, Chief Legal Officer | Sale | 6,574 | $256 |
| Aug 7, 2026 | Duato Joaquin · director, officer: CEO and Chairman of the Board | Sale | 41,957 | $258 |
| Aug 7, 2026 | Duato Joaquin · director, officer: CEO and Chairman of the Board | Sale | 6,523 | $259 |
| Aug 7, 2026 | Forminard Elizabeth · officer: EVP, Chief Legal Officer | Sale | 9,344 | $258 |
| Jul 21, 2026 | Broadhurst Vanessa · officer: EVP, Global Corp Affairs | M-Exempt | 11,925 | $132 |
| Jul 21, 2026 | Broadhurst Vanessa · officer: EVP, Global Corp Affairs | M-Exempt | 11,129 | $130 |
| Jul 21, 2026 | Broadhurst Vanessa · officer: EVP, Global Corp Affairs | Sale | 23,054 | $251 |
| Jun 12, 2026 | Wengel Kathryn E · officer: EVP, Chief TO and Risk Officer | Sale | 10,000 | $241 |
| Jun 12, 2026 | Wengel Kathryn E · officer: EVP, Chief TO and Risk Officer | M-Exempt | 10,000 | $116 |
| Jun 11, 2026 | Woods Eugene A. · director | A-Award | 161 | $0.00 |
| Jun 11, 2026 | Pinto Daniel E · director | A-Award | 134 | $0.00 |
| Jun 11, 2026 | HEWSON MARILLYN A · director | A-Award | 215 | $0.00 |
| May 4, 2026 | REED JOHN C · officer: EVP, Innovative Medicine, R&D | M-Exempt | 25,255 | $0.00 |
| May 4, 2026 | REED JOHN C · officer: EVP, Innovative Medicine, R&D | F-InKind | 11,002 | $230 |
| Apr 27, 2026 | Beckerle Mary C · director | A-Award | 975 | $0.00 |
| Apr 27, 2026 | HEWSON MARILLYN A · director | A-Award | 975 | $0.00 |
| Apr 27, 2026 | Johnson Paula A · director | A-Award | 975 | $0.00 |
| Apr 27, 2026 | Doudna Jennifer A · director | A-Award | 975 | $0.00 |
| Apr 27, 2026 | McClellan Mark B. · director | A-Award | 975 | $0.00 |
| Apr 27, 2026 | MORIKIS JOHN G · director | A-Award | 1,540 | $0.00 |
| Apr 27, 2026 | West Nadja · director | A-Award | 975 | $0.00 |
| Apr 27, 2026 | Woods Eugene A. · director | A-Award | 975 | $0.00 |
| Apr 27, 2026 | Joly Hubert · director | A-Award | 975 | $0.00 |
| Apr 27, 2026 | Pinto Daniel E · director | A-Award | 1,712 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 539Increased 3758Reduced 4092Sold out 126
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BLACKROCK, INC. | Increased | 213,385,546 | May 13, 2026 |
| BlackRock, Inc. | Reduced | 212,098,264 | Aug 7, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 157,226,374 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 156,605,370 | May 15, 2026 |
| STATE STREET CORP | Increased | 133,776,025 | Aug 7, 2026 |
| STATE STREET CORP | Reduced | 133,476,288 | May 15, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 64,370,816 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 63,514,436 | May 8, 2026 |
| JPMORGAN CHASE & CO | Increased | 63,096,344 | May 13, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 59,164,862 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Reduced | 59,086,417 | Aug 12, 2026 |
| JPMORGAN CHASE & CO | Reduced | 58,301,609 | Aug 12, 2026 |
| MORGAN STANLEY | Increased | 44,808,254 | Aug 13, 2026 |
| MORGAN STANLEY | Reduced | 44,721,167 | May 15, 2026 |
| NORGES BANK | New Position | 31,825,084 | Aug 12, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 18, 2026